Latest news with #Diwan
Time of India
4 days ago
- Business
- Time of India
Kanakia, hines tie up for ₹3,000 crore office project in Mumbai
Mumbai: US-headquartered real estate investment manager Hines and Mumbai-based property developer Kanakia Group have entered into an alliance to develop a commercial office project on a 3-acre land parcel near Bandra-Kurla Complex (BKC) with a total investment of around ₹3,000 crore. The alliance has further partnered with Japanese conglomerate Sumitomo Corporation and real estate firm Mitsubishi Estate for the development spanning 1.5 million sq ft premium office spaces. Of the total investment, the equity investment will be about ₹1,025 crore. "This project marks a significant milestone in our journey in India," said Amit Diwan, senior managing director and head of India at Hines. "It reflects our commitment to deepening our presence in Mumbai and highlights our strategic partnerships with MEC and Sumitomo." As per the terms of the joint development agreement, landowner Kanakia Group will be responsible for the approvals, while the investment will be made by Hines and the Japanese entities. In addition to their investment, Hines, Sumitomo and Mitsubishi Estate will execute the development. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Perdagangkan CFD Emas dengan Broker Tepercaya IC Markets Mendaftar Undo "This formation of this alliance with Hines, Mitsubishi and Sumitomo has allowed us to deleverage our balance sheet in a significant manner. The approvals for the project have already been secured and we expect the development to be completed by the end of 2028," said Rasesh B Kanakia, chairman, Kanakia Group. The project, comprising 12 upper floors and seven basements in Mumbai's business district, will see Mitsubishi holding a 50% stake in the development, marking its maiden project in the city and fifth in India. Diwan, Kanakia and property consultant JLL India, which acted as the advisor for the transaction, declined to comment on the project's investment specifics. Live Events The project is located on a corner site facing the Santacruz-Chembur Link Road and a connecting road to the BKC district. "Given India's strong demographic tailwinds, along with the right fundamentals and market conditions, we've been seeing more investor interest in the country and continued demand for our office and residential projects," said Diwan.
Miami Herald
6 days ago
- Business
- Miami Herald
NanoViricides to Present at the BIO International Convention in Boston on Monday, June 16, 2025
SHELTON, CT / ACCESS Newswire / May 28, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the virus cannot escape, announced that it will be presenting on Monday, June 16th, at 2:30pm at the BIO International Convention 2025 in Boston, MA. Event Information: Anil R. Diwan, PhD, President and Executive Chairman of the Company will provide an update on the Company, its Drug Pipeline and Platform Technologies available for licensing. Dr. Diwan will also be available for meetings in the BIO Partnering™ match-making platform during the Convention from June 16th through June 19th, 2025. NanoViricides' Current Antiviral Drugs Pipeline NanoViricides is rapidly moving towards Phase II Safety, Tolerability and Efficacy Evaluation of its Lead Drug candidate, NV-387, for the Treatment of MPOX disease, in response to the continuing Public Health Emergency of International Concern in WHO African Region. NV-387 is a revolutionary broad-spectrum drug candidate designed to mimic host-side features that the virus particle uses as the first landing site in order to mount a cellular infection. An estimated 90-95% of human pathogens utilize the same common landing feature that is mimicked by NV-387, giving the drug its extremely broad antiviral spectrum. NV-387 was found to be highly effective against the "tripledemic" respiratory viruses, namely RSV, Influenza A, and Coronaviruses, in respective lethal animal models of lung infection. In all of these cases, NV-387 was substantially superior to existing drugs. The virus cannot escape NV-387 even as it changes in the field, because the virus continues to use the sulfated proteoglycan features for attachment despite all changes. This is completely unlike existing vaccines, antibodies, and small chemical anti-viral modalities that are all readily defeated by viruses by relatively small changes, often in single viral proteins. The overall market size of NV-387 indications is estimated to be well in excess of $10 billion. NV-387 is expected to become an "emperic therapy" for viral infections, just as antibiotics such as amoxicillin are used as emperic therapies for bacterial infections. NV-387 would be the first ever drug enabling emperic antiviral therapy, and would be potentially as revolutionary to antiviral therapy as antibiotics have been to anti-bacterial therapy. Emperic therapy means when the patient presents to the doctor, immediately the antiviral drug can be prescribed and started without having to wait for discriminating test results as to which virus is causing the infection. This has tremendous benefits since antiviral drugs are most effective when given as early as possible upon viral infection. In addition, the Company has developed a clinical-ready pan-herpesvirus drug candidate, NV-HHV-1 that has shown activity against HSV-1, HSV-2 and VZV, and is expected to have activity against CMV, HHV-6, and HHV-8 as well. The Company has also developed an anti-HIV drug candidate, NV-HIV-1, that has shown strong efficacy in SCID-hu-Thy-Liv animal model of HIV infection. NV-HHV-1 mimics the landing site on cellular CD4 that is required for all HIV viruses to cause cellular infection. Thus, HIV, despite constant changes, will be unable to escape NV-HHV-1. NanoViricide Platform Enables Drug Rescue, Oral Drug Delivery, and Zip-Code-Specific Delivery Oral drug delivery of small chemicals, peptides (such as the GLP-a obesity drugs), and proteins is feasible by encapsulation of the guest drug into the nanoviricide polymeric micelle. The encapsulation protects the guest from metabolism thereby enabling effective drug delivery. Encapsulation of a difficult or failed drug within the nanoviricide polymeric micelle can enable rescue of the drug candidate turning it into a clinically viable drug candidate, saving hundreds of millions of dollars of development work. Going another step further, the nanoviricide platform technology can be customized to enable zip-code-like specific delivery of encapsulated drugs to specific tissues (e.g. non-liver targeted delivery),, cells (e.g. cancer-cell specific delivery sparing normal cells), bacteria, or viruses (e.g. NV-HHV-1, NV-HIV-1) in a fully synthetic chemistry based, scalable technology stack. ABOUT BIO INTERNATIONAL CONVENTION The BIO International Convention is the largest and most comprehensive event for biotechnology, representing the full ecosystem of biotech with 20,000 industry leaders from across the globe. In a time of remarkable discovery and progress, the biotechnology industry stands at the forefront of a revolution changing how we live, heal, and care. From pioneering treatments offering hope to millions, to sustainable agricultural innovations to feed a growing population, or environmental breakthroughs securing our future, biotech drives positive change faster than ever. This progress is not just a change but a promise for a brighter future. The world is ready. Whether you work at a public pharmaceutical company, biotech startup, academia, non-profit organization, or government agency; or you work as a researcher, business development professional or investor, BIO is where you'll make valuable connections and build relationships. Our proprietary BIO Partnering™ match-making platform-exclusive to the Premier Access registration package-allows you to find potential partners, schedule and accept meetings. ABOUT NANOVIRICIDES NanoViricides, Inc. (the "Company") ( is a clinical stage company that is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide™ class of drug candidates and the nanoviricide™ technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. The Company has a Memorandum of Understanding with TheraCour for the development of drugs based on these technologies for all antiviral infections. The MoU does not include cancer and similar diseases that may have viral origin but require different kinds of treatments. The Company has obtained broad, exclusive, sub-licensable, field licenses to drugs developed in several licensed fields from TheraCour Pharma, Inc. The Company's business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005. Our lead drug candidate is NV-387, a broad-spectrum antiviral drug that we plan to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. Our other advanced drug candidate is NV-HHV-1 for the treatment of Shingles. The Company cannot project an exact date for filing an IND for any of its drugs because of dependence on a number of external collaborators and consultants. The Company is currently focused on advancing NV-387 into Phase II human clinical trials. NV-CoV-2 (API NV-387) is our nanoviricide drug candidate for COVID-19 that does not encapsulate remdesivir. NV-CoV-2-R is our other drug candidate for COVID-19 that is made up of NV-387 with remdesivir encapsulated within its polymeric micelles. The Company believes that since remdesivir is already US FDA approved, our drug candidate encapsulating remdesivir is likely to be an approvable drug, if safety is comparable. Remdesivir is developed by Gilead. The Company has developed both of its own drug candidates NV-CoV-2 and NV-CoV-2-R independently. The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides' platform technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The Company intends to obtain a license for RSV, Poxviruses, and/or Enteroviruses if the initial research is successful. As is customary, the Company must state the risk factor that the path to typical drug development of any pharmaceutical product is extremely lengthy and requires substantial capital. As with any drug development efforts by any company, there can be no assurance at this time that any of the Company's pharmaceutical candidates would show sufficient effectiveness and safety for human clinical development. Further, there can be no assurance at this time that successful results against coronavirus in our lab will lead to successful clinical trials or a successful pharmaceutical product. This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in preclinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products. The phrases "safety", "effectiveness" and equivalent phrases as used in this press release refer to research findings including clinical trials as the customary research usage and do not indicate evaluation of safety or effectiveness by the US FDA. FDA refers to US Food and Drug Administration. IND application refers to "Investigational New Drug" application. cGMP refers to current Good Manufacturing Practices. CMC refers to "Chemistry, Manufacture, and Controls". CHMP refers to the Committee for Medicinal Products for Human Use, which is the European Medicines Agency's (EMA) committee responsible for human medicines. API stands for "Active Pharmaceutical Ingredient". WHO is the World Health Organization. R&D refers to Research and Development. Contact:NanoViricides, Public Relations Contact:ir@ SOURCE: NanoViricides, Inc.
Kuwait Times
27-05-2025
- Politics
- Kuwait Times
Crown Prince meets Philippines, Cambodia leaders in Kuala Lampur
Sheikh Sabah Al-Khaled meets with Prime Minister Dr Hun Manet of Cambodia. KUALA LUMPUR: Representing His Highness the Amir Sheikh Meshal Al-Ahmad Al-Jaber Al-Sabah, His Highness the Crown Prince Sheikh Sabah Al-Khaled Al-Hamad Al-Sabah held separate meetings with President Ferdinand Marcos Jr of the Philippines and Prime Minister Dr Hun Manet of Cambodia on the sidelines of the second ASEAN-Gulf Cooperation Council (GCC) summit and the ASEAN-GCC-China summit in Kuala Lumpur At the start of the meeting with President Marcos, the Crown Prince conveyed greetings from His Highness the Amir to the Philippine leader. Both sides reviewed the bilateral relations between Kuwait and the Philippines, exploring ways to further strengthen and develop cooperation in areas of mutual interest. They also discussed recent regional and international developments. During the meeting with Prime Minister Hun Manet, the two parties examined the current state of bilateral relations between Kuwait and Cambodia. Discussions focused on supporting and enhancing these relations for the benefit of both countries and their peoples, alongside exchanges on key regional and global issues. Both meetings were attended by Foreign Minister Abdullah Ali Al-Yahya, Undersecretary for Foreign Affairs at the Crown Prince's Diwan Mazen Issa Al-Issa, Assistant Foreign Minister for the Minister's Office Affairs Ambassador Bader Saleh Al-Tunayan, Assistant Foreign Minister for Asian Affairs Ambassador Sameeh Johar Hayat, with Kuwait's Ambassador to Malaysia Rashid Mohammed Al-Saleh also present during the Cambodia meeting. — KUNA
The Hindu
29-04-2025
- Business
- The Hindu
Vizhinjam set to celebrate its storied past
Vizhinjam has a venerable past with its history of maritime trade dating back to the second century BCE. Once again the old maritime hub is in the news with the Vizhinjam international seaport set to be commissioned by Prime Minister Narendra Modi on Friday. It is believed that Vizhinjam was developed into a small port by Raja Kesavadas, who was the Diwan of Travancore during the reign of Dharma Raja Karthika Thirunal Rama Varma. However, the idea for a modern port at Vizhinjam was first mooted by Diwan Sir C. P. Ramaswamy Iyer when he was the Diwan of erstwhile Travancore State. British engineer The survey was carried out in themid-1940s and was led by a British engineer who arrived in Travancore to study the sea at Vizhinjam and its shore. A Vizhinjam Harbour Special Section was founded in 1946 under the airport division of the Public Works department at the time. However, the work got stalled when the country earned independence. However, as the commissioning of the port approaches, it seems that the authorities have forgotten the initial group who did the survey for developing Vizhinjam into a major seaport. G.G. Menon of Thiruvananthapuram, an engineer who retired from the Kerala Public Works department (PWD) and turns 103 next month, was part of the team of engineers who started the survey in the 1940s for Vizhinjam's development into a seaport as per orders of Ramaswamy Iyer. As the seaport is now getting ready for its commissioning, the only voice which remembers the arduous task the team undertook in the mid-40s to carry out the survey by going into the sea in small catamarans with imported instruments is forgotten. Speaking to The Hindu Sasikumar Menon, his son, said no one from the State government has contacted him or invited him to the opening ceremony. According to Mr. Menon, Ramaswamy Iyer perceived the possibility of a commercial seaport at Vizhinjam with even plans to link the Vellayani lake to the port with a channel. The survey team in which Mr. Menon was a part travelled the length and breadth of the sea in the region in small boats to survey the depth and tide variations up to one nautical mile as part of preparing layout, water availability, and other details. Though the project was dropped by the then government and the officers in the Harbour Division were relocated to other departments, it gained momentum again in 1995 when the then government took an initiative to sign a memorandum of understanding (MoU) with Kumar Energy Corporation, a Hyderabad-based company, for the development of a port on a Build-Operate-Transfer (BOT) basis. Cancelled later It was also cancelled later. A decade after this, a feasibility study was conducted again in 2004, and it was decided to build a port at Vizhinjam, adjacent to the existing fishing harbour. Based on the study, the first global bid was floated in 2005, although the bid was not successful due to security reasons. Later, bids were floated again in 2007, 2010, and finally in 2014, which paved the way for Vizhinjam to turn into a transshipment hub to transform the whole nation, marking its own space in the global maritime trade.
Al Etihad
24-04-2025
- Politics
- Al Etihad
Sharjah Ruler arrives in Sultanate of Oman
24 Apr 2025 16:33 SHARJAH (WAM)His Highness Sheikh Dr. Sultan bin Mohammad Al Qasimi, Supreme Council Member and Ruler of Sharjah, on Thursday, arrived in the Omani capital, his visit, the Ruler of Sharjah is scheduled to meet with His Majesty Sultan Haitham bin Tariq of Oman and attend events at the Muscat International Book his arrival at the Royal Airport, His Highness was received by Khalid bin Hilal Al Busaidi, Minister of the Diwan of the Royal Court. Accompanying His Highness is a delegation that includes: Sheikha Bodour bint Sultan Al Qasimi, Chairperson of the Sharjah Book Authority, Mohammed bin Nekhaira Al Dhaheri, UAE Ambassador to the Sultanate of Oman, Abdullah bin Mohammed Al Owais, Chairman of the Department of Culture, Ahmed bin Rakkad Al Ameri, CEO of the Sharjah Book Authority, Mohammed Obaid Al Zaabi, Head of the Department of Protocol and Hospitality, Mohamed Hassan Khalaf, Director General of Sharjah Broadcasting Authority, Tariq Saeed Allay, Director General of the Sharjah Government Media Bureau.
